

Christopher D Byrne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/632922/publications.pdf>

Version: 2024-02-01

322
papers

20,479
citations

9264

74
h-index

13379

130
g-index

330
all docs

330
docs citations

330
times ranked

19821
citing authors

#	ARTICLE	IF	CITATIONS
1	NAFLD: A multisystem disease. <i>Journal of Hepatology</i> , 2015, 62, S47-S64.	3.7	2,037
2	Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. <i>Journal of Hepatology</i> , 2016, 65, 589-600.	3.7	965
3	Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. <i>Diabetes Care</i> , 2018, 41, 372-382.	8.6	407
4	Maternal high-fat feeding primes steatohepatitis in adult mice offspring, involving mitochondrial dysfunction and altered lipogenesis gene expression. <i>Hepatology</i> , 2009, 50, 1796-1808.	7.3	391
5	Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. <i>European Heart Journal</i> , 2012, 33, 1190-1200.	2.2	372
6	NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications. <i>Gut</i> , 2020, 69, 1691-1705.	12.1	369
7	Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. <i>Digestive and Liver Disease</i> , 2015, 47, 997-1006.	0.9	368
8	The complex link between NAFLD and type 2 diabetes mellitus – mechanisms and treatments. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 599-612.	17.8	346
9	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78.	17.8	330
10	COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. <i>Journal of Clinical and Translational Hepatology</i> , 2020, 8, 1-7.	1.4	329
11	Obesity Is a Risk Factor for Greater COVID-19 Severity. <i>Diabetes Care</i> , 2020, 43, e72-e74.	8.6	323
12	Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2018, 14, 99-114.	9.6	284
13	Complications, morbidity and mortality of nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154170.	3.4	278
14	Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: Results from the WELCOME* study. <i>Hepatology</i> , 2014, 60, 1211-1221.	7.3	263
15	Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 79, 64-76.	3.4	261
16	Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 483-495.	3.6	259
17	NAFLD as a driver of chronic kidney disease. <i>Journal of Hepatology</i> , 2020, 72, 785-801.	3.7	249
18	Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals. <i>Gut</i> , 2021, 70, 962-969.	12.1	238

#	ARTICLE	IF	CITATIONS
19	Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 903-913.	8.1	227
20	Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease. <i>Nature Reviews Nephrology</i> , 2017, 13, 297-310.	9.6	219
21	Metabolic disturbances in non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2009, 116, 539-564.	4.3	210
22	Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. <i>World Journal of Gastroenterology</i> , 2014, 20, 1724.	3.3	207
23	Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 578-588.	8.1	206
24	Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1236-1248.	2.6	196
25	MAFLD and risk of CKD. <i>Metabolism: Clinical and Experimental</i> , 2021, 115, 154433.	3.4	178
26	Combined Influence of Insulin Resistance, Overweight/Obesity, and Fatty Liver as Risk Factors for Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 717-722.	8.6	176
27	Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2021, 18, 24-39.	17.8	174
28	Increased Glucocorticoid Receptor Expression in Human Skeletal Muscle Cells May Contribute to the Pathogenesis of the Metabolic Syndrome. <i>Diabetes</i> , 2002, 51, 1066-1075.	0.6	167
29	Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. <i>Gut</i> , 2020, 69, 1545-1547.	12.1	166
30	CKD and Nonalcoholic Fatty Liver Disease. <i>American Journal of Kidney Diseases</i> , 2014, 64, 638-652.	1.9	163
31	Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis. <i>Gut</i> , 2022, 71, 156-162.	12.1	162
32	The 30 Minute Insulin Incremental Response in an Oral Glucose Tolerance Test as a Measure of Insulin Secretion. <i>Diabetic Medicine</i> , 1995, 12, 931-931.	2.3	161
33	Fasting proinsulin concentrations predict the development of type 2 diabetes. <i>Diabetes Care</i> , 1999, 22, 262-270.	8.6	158
34	Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). <i>Drug Discovery Today</i> , 2007, 12, 740-747.	6.4	158
35	Undiagnosed Glucose Intolerance in the Community: the Isle of Ely Diabetes Project. <i>Diabetic Medicine</i> , 1995, 12, 30-35.	2.3	154
36	Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. <i>PLoS ONE</i> , 2013, 8, e57183.	2.5	153

#	ARTICLE	IF	CITATIONS
37	Resolution of Fatty Liver and Risk of Incident Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3637-3643.	3.6	143
38	Thrombin Generation by Apoptotic Vascular Smooth Muscle Cells. <i>Blood</i> , 1997, 89, 4378-4384.	1.4	140
39	Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: a meta-analysis of observational cohort studies. <i>Gut</i> , 2022, 71, 778-788.	12.1	132
40	Extrapulmonary complications of COVID-19: A multisystem disease?. <i>Journal of Medical Virology</i> , 2021, 93, 323-335.	5.0	131
41	Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study. <i>Gut</i> , 2019, 68, 1667-1675.	12.1	130
42	Nonalcoholic Fatty Liver Disease Is Independently Associated With an Increased Incidence of Chronic Kidney Disease in Patients With Type 1 Diabetes. <i>Diabetes Care</i> , 2014, 37, 1729-1736.	8.6	129
43	Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. <i>Journal of Hepatology</i> , 2017, 66, 1031-1036.	3.7	128
44	Fatty Liver, Insulin Resistance, and Features of Metabolic Syndrome. <i>Diabetes Care</i> , 2012, 35, 2359-2364.	8.6	125
45	Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. <i>Journal of Hepatology</i> , 2014, 60, 1040-1045.	3.7	124
46	Ectopic Fat, Insulin Resistance, and Nonalcoholic Fatty Liver Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2014, 34, 1155-1161.	2.4	124
47	Patients with diabetes are at higher risk for severe illness from COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 335-337.	2.9	124
48	The metabolic syndrome: common origins of a multifactorial disorder. <i>Postgraduate Medical Journal</i> , 2009, 85, 614-621.	1.8	123
49	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1597-1610.e7.	1.3	123
50	Effects of maternal iron restriction in the rat on hypoxia-induced gene expression and fetal metabolite levels. <i>British Journal of Nutrition</i> , 2001, 85, 193-201.	2.3	117
51	Nonalcoholic Fatty Liver Disease in Children. <i>Seminars in Liver Disease</i> , 2018, 38, 001-013.	3.6	108
52	Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. <i>Hepatology</i> , 2016, 64, 1388-1389.	7.3	104
53	<sc>Nonalcoholic fatty liver disease</sc> as a metabolic disease in humans: A literature review. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1069-1083.	4.4	104
54	Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action. <i>Molecular Aspects of Medicine</i> , 2018, 64, 135-146.	6.4	103

#	ARTICLE	IF	CITATIONS
55	Effect of exercise on the development of new fatty liver and the resolution of existing fatty liver. <i>Journal of Hepatology</i> , 2016, 65, 791-797.	3.7	102
56	Administrative Coding in Electronic Health Care Records—Based Research of NAFLD: An Expert Panel Consensus Statement. <i>Hepatology</i> , 2021, 74, 474-482.	7.3	102
57	Atherogenic Lipoproteins Support Assembly of the Prothrombinase Complex and Thrombin Generation: Modulation by Oxidation and Vitamin E. <i>Blood</i> , 1998, 91, 508-515.	1.4	99
58	Bidirectional Relationships and Disconnects between NAFLD and Features of the Metabolic Syndrome. <i>International Journal of Molecular Sciences</i> , 2016, 17, 367.	4.1	96
59	Impact of metabolic syndrome criteria on cardiovascular disease risk in people with newly diagnosed type 2 diabetes. <i>Diabetologia</i> , 2006, 49, 49-55.	6.3	94
60	Fatty liver: Role of inflammation and fatty acid nutrition. <i>Prostaglandins Leukotrienes and Essential Fatty Acids</i> , 2010, 82, 265-271.	2.2	93
61	Views of People With High and Low Levels of Health Literacy About a Digital Intervention to Promote Physical Activity for Diabetes: A Qualitative Study in Five Countries. <i>Journal of Medical Internet Research</i> , 2015, 17, e230.	4.3	93
62	Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission. <i>Diabetes Care</i> , 2018, 41, 341-347.	8.6	92
63	Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 367-378.	8.1	92
64	Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial. <i>Journal of Hepatology</i> , 2015, 63, 1476-1483.	3.7	90
65	Non-esterified fatty acid concentrations are independently associated with hepatic steatosis in obese subjects. <i>Diabetologia</i> , 2006, 49, 141-148.	6.3	88
66	A quantitative analysis of the relationship between habitual energy expenditure, fitness and the metabolic cardiovascular syndrome. <i>British Journal of Nutrition</i> , 1998, 80, 235-241.	2.3	84
67	NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment. <i>Diabetes and Metabolism</i> , 2021, 47, 101215.	2.9	84
68	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. <i>PLoS ONE</i> , 2016, 11, e0168216.	2.5	83
69	Heart valve calcification in patients with type 2 diabetes and nonalcoholic fatty liver disease. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 879-887.	3.4	82
70	Fetal origins of adult disease: epidemiology and mechanisms. <i>Journal of Clinical Pathology</i> , 2000, 53, 822-828.	2.0	81
71	<i>Dorothy Hodgkin Lecture 2012</i> <i>*</i> Non-alcoholic fatty liver disease, insulin resistance and ectopic fat: a new problem in diabetes management. <i>Diabetic Medicine</i> , 2012, 29, 1098-1107.	2.3	81
72	Tests for diagnosing and monitoring non-alcoholic fatty liver disease in adults. <i>BMJ: British Medical Journal</i> , 2018, 362, k2734.	2.3	81

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials. <i>Diabetes and Metabolism</i> , 2020, 46, 427-441.	2.9	81
74	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. <i>Diabetologia</i> , 1994, 37, 889-896.	6.3	80
75	Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2018, 87, 1-12.	3.4	80
76	Effects of VLDL and Remnant Particles on Platelets. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 2006, 35, 281-291.	0.3	79
77	Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR. <i>Biochemical Journal</i> , 1999, 337, 231-241.	3.7	78
78	EASLâ€EASDâ€EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: is universal screening appropriate?. <i>Diabetologia</i> , 2016, 59, 1141-1144.	6.3	78
79	Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?. <i>Diabetes and Metabolism</i> , 2016, 42, 142-156.	2.9	78
80	Ectopic fat, insulin resistance and non-alcoholic fatty liver disease. <i>Proceedings of the Nutrition Society</i> , 2013, 72, 412-419.	1.0	77
81	Association of nonalcoholic fatty liver disease with QTc interval in patients with type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 663-669.	2.6	77
82	Association between nonâ€Ealcoholic fatty liver disease and risk of atrial fibrillation in adult individuals: An updated metaâ€Eanalysis. <i>Liver International</i> , 2019, 39, 758-769.	3.9	75
83	Interaction of non-esterified fatty acid and insulin in control of triacylglycerol secretion by Hep G2 cells. <i>Biochemical Journal</i> , 1991, 280, 99-104.	3.7	72
84	Association of metabolic dysfunction-associated fatty liver disease with kidney disease. <i>Nature Reviews Nephrology</i> , 2022, 18, 259-268.	9.6	72
85	Current treatment of nonâ€Ealcoholic fatty liver disease. <i>Diabetes, Obesity and Metabolism</i> , 2009, 11, 188-195.	4.4	70
86	Diagnosis and management of non-alcoholic fatty liver disease. <i>Postgraduate Medical Journal</i> , 2019, 95, 314-322.	1.8	70
87	Type 2 diabetes and risk of hospital admission or death for chronic liver diseases. <i>Journal of Hepatology</i> , 2016, 64, 1358-1364.	3.7	67
88	<i>rs738409</i> is associated with renal glomerular and tubular injury in NAFLD patients with persistently normal ALT levels. <i>Liver International</i> , 2020, 40, 107-119.	3.9	67
89	Global epidemiology of lean nonâ€Ealcoholic fatty liver disease: A systematic review and metaâ€Eanalysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2041-2050.	2.8	67
90	Urine Albumin/Creatinine Ratio Below 30Âmg/g is a Predictor of Incident Hypertension and Cardiovascular Mortality. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	65

#	ARTICLE	IF	CITATIONS
91	Incorporating fatty liver disease in multidisciplinary care and novel clinical trial designs for patients with metabolic diseases. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 743-753.	8.1	60
92	Two variants of quantitative reverse transcriptase PCR used to show differential expression of $\hat{1}\pm$, $\hat{1}^2$ - and $\hat{1}^3$ -fibrinogen genes in rat liver lobes. <i>Biochemical Journal</i> , 1997, 321, 769-776.	3.7	57
93	Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF- $\hat{1}^2$ levels. <i>Atherosclerosis</i> , 1998, 140, 45-53.	0.8	57
94	Non-alcoholic fatty liver disease and cardiovascular risk: metabolic aspects and novel treatments. <i>Endocrine</i> , 2011, 40, 332-343.	2.3	57
95	Non-alcoholic fatty liver disease and childhood obesity. <i>Archives of Disease in Childhood</i> , 2021, 106, 3-8.	1.9	57
96	Non-Alcoholic Fatty Liver Disease (NAFLD): New challenge for general practitioners and important burden for health authorities?. <i>Primary Care Diabetes</i> , 2010, 4, 129-137.	1.8	56
97	Diagnosis and Management of Nonalcoholic Fatty Liver Disease and Its Hemostatic/Thrombotic and Vascular Complications. <i>Seminars in Thrombosis and Hemostasis</i> , 2013, 39, 214-228.	2.7	56
98	Metabolically healthy obesity and NAFLD. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2016, 13, 442-444.	17.8	55
99	Control of Hep G2-cell triacylglycerol and apolipoprotein B synthesis and secretion by polyunsaturated non-esterified fatty acids and insulin. <i>Biochemical Journal</i> , 1992, 288, 101-107.	3.7	54
100	Metabolically healthy obese subjects are at risk of fatty liver but not of pre-clinical atherosclerosis. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014, 24, 256-262.	2.6	54
101	Circulating Markers of Liver Function and Cardiovascular Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 2290-2296.	2.4	54
102	Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression. <i>Atherosclerosis</i> , 2016, 246, 13-20.	0.8	54
103	A Novel Role for CD36 in VLDL-Enhanced Platelet Activation. <i>Diabetes</i> , 2003, 52, 1248-1255.	0.6	52
104	Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study. <i>European Journal of Clinical Nutrition</i> , 2017, 71, 973-979.	2.9	51
105	Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. <i>Hepatology</i> , 2020, 71, 861-873.	7.3	49
106	Association between non-alcoholic fatty liver disease and bone turnover biomarkers in post-menopausal women with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2019, 45, 347-355.	2.9	47
107	Screening for non-alcoholic fatty liver disease using liver stiffness measurement and its association with chronic kidney disease and cardiovascular complications in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2020, 46, 296-303.	2.9	47
108	C-reactive protein and risk of cardiovascular and all-cause mortality in 268 803 East Asians. <i>European Heart Journal</i> , 2014, 35, 1809-1816.	2.2	46

#	ARTICLE	IF	CITATIONS
109	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 22-43.	8.9	46
110	Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease. <i>Journal of the American College of Cardiology</i> , 2022, 79, 180-191.	2.8	46
111	Systematic review with meta-analysis: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 375-388.	3.7	45
112	Cortisol clearance and associations with insulin sensitivity, body fat and fatty liver in middle-aged men. <i>Diabetologia</i> , 2007, 50, 1024-1032.	6.3	44
113	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. <i>Hepatology</i> , 2019, 70, 142-153.	7.3	44
114	Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2014, 37, 301-311.	1.8	42
115	All-Cause and Cardiovascular Mortality Among Koreans. <i>American Journal of Preventive Medicine</i> , 2015, 49, 62-71.	3.0	41
116	A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 345-352.	3.0	41
117	Obesity and incidence of diabetes: Effect of absence of metabolic syndrome, insulin resistance, inflammation and fatty liver. <i>Atherosclerosis</i> , 2018, 275, 50-57.	0.8	40
118	What's new in NAFLD pathogenesis, biomarkers and treatment?. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 70-71.	17.8	40
119	Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 28-43.	4.4	40
120	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2019, 71, 802-810.	3.7	39
121	Association between <i>Helicobacter pylori</i> infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis. <i>Metabolism: Clinical and Experimental</i> , 2019, 96, 56-65.	3.4	38
122	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2016, 53, 106-120.	6.1	37
123	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD. <i>Liver International</i> , 2018, 38, 342-349.	3.9	37
124	Differential priming of RNA templates during cDNA synthesis markedly affects both accuracy and reproducibility of quantitative competitive reverse-transcriptase PCR. <i>Biochemical Journal</i> , 1999, 337, 231.	3.7	36
125	Time to Replace Assessment of Liver Histology With MR-Based Imaging Tests to Assess Efficacy of Interventions for Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2016, 150, 7-10.	1.3	36
126	Association between PNPLA3rs738409 polymorphism decreased kidney function in postmenopausal type 2 diabetic women with or without non-alcoholic fatty liver disease. <i>Diabetes and Metabolism</i> , 2019, 45, 480-487.	2.9	36

#	ARTICLE	IF	CITATIONS
127	Randomised controlled trial and economic analysis of an internet-based weight management programme: POWeR+ (Positive Online Weight Reduction). <i>Health Technology Assessment</i> , 2017, 21, 1-62.	2.8	36
128	Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a sub-group of individuals with normal glucose tolerance. <i>Diabetologia</i> , 1995, 38, 1358-1366.	6.3	34
129	Triglyceride-rich lipoproteins: are links with atherosclerosis mediated by a procoagulant and proinflammatory phenotype?. <i>Atherosclerosis</i> , 1999, 145, 1-15.	0.8	34
130	Contribution of a genetic risk score to clinical prediction of hepatic steatosis in obese children and adolescents. <i>Digestive and Liver Disease</i> , 2019, 51, 1586-1592.	0.9	34
131	Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. <i>Diabetes and Metabolism</i> , 2020, 46, 505-507.	2.9	34
132	Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis. <i>Digestive Diseases</i> , 2016, 34, 11-18.	1.9	33
133	<i>PNPLA3</i> gene variant and chronic kidney disease in type 2 diabetic patients with NAFLD: Clinical and experimental findings. <i>Liver International</i> , 2020, 40, 1130-1141.	3.9	33
134	Cross-sectional but not longitudinal associations between non-esterified fatty acid levels and glucose intolerance and other features of the metabolic syndrome. <i>Diabetic Medicine</i> , 1999, 16, 1007-1015.	2.3	31
135	Late effects of childhood cancer treatment: severe hypertriglyceridaemia, central obesity, non alcoholic fatty liver disease and diabetes as complications of childhood total body irradiation. <i>Diabetic Medicine</i> , 2013, 30, e239-42.	2.3	31
136	Design and rationale of the INSYTE study: A randomised, placebo controlled study to test the efficacy of a synbiotic on liver fat, disease biomarkers and intestinal microbiota in non-alcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2018, 71, 113-123.	1.8	31
137	Causes of Mortality in Non-Alcoholic Fatty Liver Disease (NAFLD) and Alcohol Related Fatty Liver Disease (AFLD). <i>Current Pharmaceutical Design</i> , 2020, 26, 1079-1092.	1.9	31
138	Hypoxia and non-alcoholic fatty liver disease. <i>Clinical Science</i> , 2010, 118, 397-400.	4.3	30
139	Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. <i>BMC Gastroenterology</i> , 2012, 12, 84.	2.0	30
140	Low Levels of Low-Density Lipoprotein Cholesterol and Mortality Outcomes in Non-Statin Users. <i>Journal of Clinical Medicine</i> , 2019, 8, 1571.	2.4	30
141	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Meta-Analysis. <i>Hepatology</i> , 2019, 70, 812-823.	7.3	30
142	Depression and increased risk of non-alcoholic fatty liver disease in individuals with obesity. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e23.	3.9	30
143	Differential hepatic lobar gene expression in offspring exposed to altered maternal dietary protein intake. <i>American Journal of Physiology - Renal Physiology</i> , 2000, 278, G128-G136.	3.4	29
144	Nonalcoholic Fatty Liver Disease and Reduced Serum Vitamin D ³ Levels. <i>Metabolic Syndrome and Related Disorders</i> , 2013, 11, 217-228.	1.3	29

#	ARTICLE	IF	CITATIONS
145	MNK1 and MNK2 mediate adverse effects of high-fat feeding in distinct ways. <i>Scientific Reports</i> , 2016, 6, 23476.	3.3	29
146	Association of Plasma Ceramides With Myocardial Perfusion in Patients With Coronary Artery Disease Undergoing Stress Myocardial Perfusion Scintigraphy. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2018, 38, 2854-2861.	2.4	29
147	Associations between specific plasma ceramides and severity of coronary-artery stenosis assessed by coronary angiography. <i>Diabetes and Metabolism</i> , 2020, 46, 150-157.	2.9	29
148	Association between increased plasma ceramides and chronic kidney disease in patients with and without ischemic heart disease. <i>Diabetes and Metabolism</i> , 2021, 47, 101152.	2.9	28
149	An increased high-density lipoprotein cholesterol/apolipoprotein A-I ratio is associated with increased cardiovascular and all-cause mortality. <i>Heart</i> , 2015, 101, 553-558.	2.9	27
150	A Perspective on Metabolic Syndrome and Nonalcoholic Fatty Liver Disease. <i>Metabolic Syndrome and Related Disorders</i> , 2015, 13, 235-238.	1.3	27
151	Baseline and Change in Uric Acid Concentration Over Time Are Associated With Incident Hypertension in Large Korean Cohort. <i>American Journal of Hypertension</i> , 2017, 30, 42-50.	2.0	27
152	Effect of <i>PNPLA3</i> polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1057-1064.	2.8	27
153	The Global Burden of the Metabolic Syndrome and its Consequences for Diabetes and Cardiovascular Disease. , 2006, , 1-41.		26
154	Type 2 Diabetes and Hepatocellular Carcinoma: Risk Factors and Pathogenesis. <i>Current Diabetes Reports</i> , 2017, 17, 20.	4.2	26
155	Adipocyte metabolism and the metabolic syndrome. <i>Diabetes, Obesity and Metabolism</i> , 2001, 3, 129-142.	4.4	25
156	Leukocyte extracellular vesicle concentration is inversely associated with liver fibrosis severity in NAFLD. <i>Journal of Leukocyte Biology</i> , 2018, 104, 631-639.	3.3	25
157	Association between non-alcoholic fatty liver disease and decreased lung function in adults: A systematic review and meta-analysis. <i>Diabetes and Metabolism</i> , 2019, 45, 536-544.	2.9	25
158	Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. <i>Frontiers in Endocrinology</i> , 2021, 12, 604100.	3.5	25
159	Ferroptosis and metabolic dysfunction-associated fatty liver disease: Is there a link?. <i>Liver International</i> , 2022, 42, 1496-1502.	3.9	25
160	Muscle Microvascular Dysfunction in Central Obesity Is Related to Muscle Insulin Insensitivity but Is Not Reversed by High-Dose Statin Treatment. <i>Diabetes</i> , 2009, 58, 1185-1191.	0.6	24
161	Altered cellular redox status, sirtuin abundance and clock gene expression in a mouse model of developmentally primed NASH. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2016, 1861, 584-593.	2.4	24
162	Plasma N-terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with non-alcoholic fatty liver disease. <i>Liver International</i> , 2019, 39, 2317-2329.	3.9	24

#	ARTICLE	IF	CITATIONS
163	Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2019, 29, 489-495.	2.6	24
164	Higher liver stiffness scores are associated with early kidney dysfunction in patients with histologically proven non-cirrhotic NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 288-295.	2.9	24
165	Hepatocellular cystathionine β lyase/hydrogen sulfide attenuates nonalcoholic fatty liver disease by activating farnesoid X receptor. <i>Hepatology</i> , 2022, 76, 1794-1810.	7.3	24
166	A novel highly reproducible quantitative competitive RT PCR system. <i>Journal of Molecular Biology</i> , 1997, 274, 338-352.	4.2	23
167	The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the ¹³ C-ketoisocaproate breath test. <i>Journal of Breath Research</i> , 2018, 12, 046002.	3.0	23
168	Decreased lung function is associated with risk of developing non-alcoholic fatty liver disease: A longitudinal cohort study. <i>PLoS ONE</i> , 2019, 14, e0208736.	2.5	23
169	Evidence for fetal programming of obesity with a focus on putative mechanisms. <i>Nutrition Research Reviews</i> , 2004, 17, 153-162.	4.1	21
170	Functional Dilator Capacity is Independently Associated with Insulin Sensitivity and Age in Central Obesity and is not Improved by High Dose Statin Treatment. <i>Microcirculation</i> , 2011, 18, 74-84.	1.8	21
171	Increased Cardiovascular Mortality in Subjects With Metabolic Syndrome Is Largely Attributable to Diabetes and Hypertension in 159 971 Korean Adults. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 2606-2612.	3.6	21
172	Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. <i>Nephron</i> , 2020, 144, 347-350.	1.8	21
173	Differences in cortisol concentrations in South Asian and European men living in the United Kingdom. <i>Clinical Endocrinology</i> , 2006, 64, 530-534.	2.4	20
174	β -Glutamyl Transferase Is Associated with Mortality Outcomes Independently of Fatty Liver. <i>Clinical Chemistry</i> , 2015, 61, 1173-1181.	3.2	20
175	Fatty Liver, Insulin Resistance, and Obesity: Relationships With Increase in Coronary Artery Calcium Over Time. <i>Clinical Cardiology</i> , 2016, 39, 321-328.	1.8	20
176	Liver zonation in children with non-alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. <i>Liver International</i> , 2018, 38, 1102-1109.	3.9	20
177	Machine learning algorithm outperforms fibrosis markers in predicting significant fibrosis in biopsy-confirmed NAFLD. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2021, 28, 593-603.	2.6	19
178	Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial. <i>Diabetologia</i> , 2015, 58, 1916-1925.	6.3	18
179	Multi-drug approaches to NASH: what's in the development pipeline?. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 143-150.	4.1	18
180	Disabling MNK protein kinases promotes oxidative metabolism and protects against diet-induced obesity. <i>Molecular Metabolism</i> , 2020, 42, 101054.	6.5	18

#	ARTICLE	IF	CITATIONS
181	Abnormal liver enzymes in children and infants with COVID-19: A narrative review of case-series studies. <i>Pediatric Obesity</i> , 2020, 15, e12723.	2.8	18
182	Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. <i>Metabolism: Clinical and Experimental</i> , 2022, 128, 154958.	3.4	18
183	Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation. <i>Nature Reviews Endocrinology</i> , 2022, 18, 638-650.	9.6	18
184	Non-alcoholic Steatohepatitis. , 2006, , 279-303.		17
185	Nonalcoholic Fatty Liver Disease Is Associated With Higher 1-year All-Cause Rehospitalization Rates in Patients Admitted for Acute Heart Failure. <i>Medicine (United States)</i> , 2016, 95, e2760.	1.0	17
186	Non-alcoholic fatty liver disease: a multi-system disease influenced by ageing and sex, and affected by adipose tissue and intestinal function. <i>Proceedings of the Nutrition Society</i> , 2022, 81, 146-161.	1.0	17
187	Potential therapeutic uses for ezetimibe beyond lowering LDL to decrease cardiovascular events. <i>Diabetes, Obesity and Metabolism</i> , 2010, 12, 958-966.	4.4	16
188	Body mass index and mortality: understanding the patterns and paradoxes. <i>BMJ, The</i> , 2016, 353, i2433.	6.0	16
189	Association between plasma ceramides and inducible myocardial ischemia in patients with established or suspected coronary artery disease undergoing myocardial perfusion scintigraphy. <i>Metabolism: Clinical and Experimental</i> , 2018, 85, 305-312.	3.4	15
190	Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1804-1812.	2.8	15
191	Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 230-237.	1.4	15
192	The association between free fatty acid concentrations and triglyceride-rich lipoproteins in the post-prandial state is altered by a common deletion polymorphism of the apo B signal peptide. <i>Atherosclerosis</i> , 1996, 127, 35-42.	0.8	14
193	IS PLATELET PHOSPHOLIPID-DEPENDENT THROMBIN GENERATION ALTERED BY ACUTE MYOCARDIAL INFARCTION OR ASPIRIN?. <i>Thrombosis Research</i> , 1996, 83, 329-338.	1.7	14
194	ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. <i>American Journal of Gastroenterology</i> , 2020, 115, 1544-1544.	0.4	14
195	Association between non-alcoholic fatty liver disease and impaired cardiac sympathetic/parasympathetic balance in subjects with and without type 2 diabetes – The Cooperative Health Research in South Tyrol (CHRIS)-NAFLD sub-study. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 3464-3473.	2.6	14
196	acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. <i>EClinicalMedicine</i> , 2021, 41, 101145.	7.1	14
197	Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?. <i>Drug Discovery Today</i> , 2010, 15, 590-595.	6.4	13
198	Lived experience of Silver-Russell syndrome: implications for management during childhood and into adulthood. <i>Archives of Disease in Childhood</i> , 2019, 104, 76-82.	1.9	13

#	ARTICLE	IF	CITATIONS
199	In vitro effects of Bifidobacterium lactis-based synbiotics on human faecal bacteria. Food Research International, 2020, 128, 108776.	6.2	13
200	Growth differentiation factor-15 and the association between type 2 diabetes and liver fibrosis in NAFLD. Nutrition and Diabetes, 2021, 11, 32.	3.2	13
201	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00417.	2.5	13
202	NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status. Hepatology, 2022, 76, 1755-1765.	7.3	13
203	The reduced cost of providing a nationally recognised service for familial hypercholesterolaemia. Open Heart, 2014, 1, e000015.	2.3	12
204	High-sensitivity C-reactive Protein Is Associated with the Presence of Coronary Artery Calcium in Subjects with Normal Blood Pressure but Not in Subjects with Hypertension. Archives of Medical Research, 2014, 45, 170-176.	3.3	12
205	Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents. Liver International, 2018, 38, 2301-2308.	3.9	12
206	Optimal thresholds for ultrasound attenuation parameter in the evaluation of hepatic steatosis severity: evidence from a cohort of patients with biopsy-proven fatty liver disease. European Journal of Gastroenterology and Hepatology, 2021, 33, 430-435.	1.6	12
207	Diastolic function is strongly and independently associated with cardiorespiratory fitness in central obesity. Journal of Applied Physiology, 2010, 108, 1568-1574.	2.5	11
208	A Bayesian network for modelling blood glucose concentration and exercise in type 1 diabetes. Statistical Methods in Medical Research, 2015, 24, 342-372.	1.5	11
209	Maternal Obesity during Pregnancy Alters Daily Activity and Feeding Cycles, and Hypothalamic Clock Gene Expression in Adult Male Mouse Offspring. International Journal of Molecular Sciences, 2019, 20, 5408.	4.1	11
210	<i>FNDC5</i> polymorphism influences the association between sarcopenia and liver fibrosis in adults with biopsy-proven non-alcoholic fatty liver disease. British Journal of Nutrition, 2021, 126, 813-824.	2.3	11
211	Non-alcoholic fatty liver disease is a risk factor for cardiovascular and cardiac diseases: further evidence that a holistic approach to treatment is needed. Gut, 2022, 71, 1695-1696.	12.1	11
212	Evaluation of Bioelectrical Impedance Analysis for Identifying Overweight Individuals at Increased Cardiometabolic Risk: A Cross-Sectional Study. PLoS ONE, 2014, 9, e106134.	2.5	11
213	Skeletal muscle mass to visceral fat area ratio as a predictor of NAFLD in lean and overweight men and women with effect modification by sex. Hepatology Communications, 2022, 6, 2238-2252.	4.3	11
214	Is an exaggerated postprandial triglyceride response associated with the component features of the insulin resistance syndrome?. , 1997, 14, 942-950.		10
215	Skeletal muscle microvascular exchange capacity is associated with hyperglycaemia in subjects with central obesity. Diabetic Medicine, 2009, 26, 1112-1119.	2.3	10
216	Gallstone Disease and Increased Risk of Ischemic Heart Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 2073-2075.	2.4	10

#	ARTICLE	IF	CITATIONS
217	Mulberry extract to modulate Blood glucose Responses in normoglycaemic adults (MULBERRY): study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 486.	1.6	10
218	Liver fat: a relevant target for dietary intervention? Summary of a Unilever workshop. <i>Journal of Nutritional Science</i> , 2017, 6, e15.	1.9	10
219	Resolution of fatty liver and weight loss: Independent associations with changes in serum lipids and apolipoproteins. <i>Atherosclerosis</i> , 2018, 272, 47-53.	0.8	10
220	Old and new classes of glucose-lowering agents as treatments for non-alcoholic fatty liver disease: A narrative review. <i>Clinical and Molecular Hepatology</i> , 2022, 28, 725-738.	8.9	10
221	All cause mortality and body mass index in a young Asian occupational cohort without baseline metabolic syndrome components. <i>International Journal of Cardiology</i> , 2016, 224, 271-278.	1.7	9
222	Cardiovascular Health Metrics in the Development and Regression of Nonalcoholic Fatty Liver Disease: A Cohort Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 610.	2.4	9
223	Multi-domain analysis of microvascular flow motion dynamics in NAFLD. <i>Microcirculation</i> , 2019, 26, e12538.	1.8	9
224	Lower levels of plasma NT-proBNP are associated with higher prevalence of NASH in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2020, 30, 1820-1825.	2.6	9
225	Non-invasive liver fibrosis scores are strongly associated with liver cancer mortality in general population without liver disease. <i>Liver International</i> , 2020, 40, 1303-1315.	3.9	9
226	Weight Change and the Development of Nonalcoholic Fatty Liver Disease in Metabolically Healthy Overweight Individuals. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e583-e599.	4.4	9
227	Hypertriglyceridaemia in subjects with normal and abnormal glucose tolerance: relative contributions of insulin secretion, insulin resistance and suppression of plasma non-esterified fatty acids. <i>Diabetologia</i> , 1994, 37, 889-896.	6.3	9
228	Lifestyle Interventions for Non-Obese Patients Both with, and at Risk, of Non-Alcoholic Fatty Liver Disease. <i>Diabetes and Metabolism Journal</i> , 2022, 46, 391-401.	4.7	9
229	Banting memorial lecture 2022: "Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime". <i>Diabetic Medicine</i> , 2022, 39, .	2.3	9
230	Sex influences the association between appendicular skeletal muscle mass to visceral fat area ratio and non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease. <i>British Journal of Nutrition</i> , 2022, 127, 1613-1620.	2.3	8
231	The HSD17B13 rs72613567 variant is associated with lower levels of albuminuria in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 1822-1831.	2.6	8
232	Non-alcoholic fatty liver disease: A risk factor for myocardial dysfunction?. <i>Journal of Hepatology</i> , 2018, 68, 640-642.	3.7	7
233	Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial. <i>Clinical Nutrition</i> , 2019, 38, 1952-1955.	5.0	7
234	Non-invasive fibrosis assessment in non-alcoholic fatty liver disease. <i>Chinese Medical Journal</i> , 2020, 133, 2743-2745.	2.3	7

#	ARTICLE	IF	CITATIONS
235	Association between positivity of serum autoantibodies and liver disease severity in patients with biopsy-proven NAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2021, 31, 552-560.	2.6	7
236	Daily Energy Expenditure, Cardiorespiratory Fitness and Glycaemic Control in People with Type 1 Diabetes. <i>PLoS ONE</i> , 2014, 9, e97534.	2.5	7
237	Resolution of, and Risk of Incident Non-alcoholic Fatty Liver Disease With Changes in Serum 25-hydroxy Vitamin D Status. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e3437-e3447.	3.6	7
238	Portal hypertension in nonalcoholic fatty liver disease: Challenges and perspectives. , 2022, 1, 57-65.		7
239	Machine learning algorithms based on proteomic data mining accurately predicting the recurrence of hepatitis B-related hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, 37, 2145-2153.	2.8	7
240	Pathological bone fractures preceded by sustained hypercalcaemia in type 1 Gaucher disease. <i>Journal of Inherited Metabolic Disease</i> , 1997, 20, 709-710.	3.6	6
241	Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial. <i>Diabetologia</i> , 2016, 59, 1422-1429.	6.3	6
242	Ad Libitum Mediterranean or Low-fat Diets as Treatments for Nonalcoholic Fatty Liver Disease?. <i>Hepatology</i> , 2018, 68, 1668-1671.	7.3	6
243	Non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 9-10.	8.1	6
244	Experiences of adolescents living with Silver-Russell syndrome. <i>Archives of Disease in Childhood</i> , 2021, 106, 1195-1201.	1.9	6
245	Individualized Polygenic Risk Score Identifies NASH in the Eastern Asia Region: A Derivation and Validation Study. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00321.	2.5	6
246	TA allele of rs2070673 in the <i>CYP2E1</i> gene is associated with lobular inflammation and nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2925-2934.	2.8	6
247	A novel quantitative ultrasound technique for identifying non-alcoholic steatohepatitis. <i>Liver International</i> , 2022, 42, 80-91.	3.9	6
248	Decrease in Sleep Duration and Poor Sleep Quality over Time Is Associated with an Increased Risk of Incident Non-Alcoholic Fatty Liver Disease. <i>Journal of Personalized Medicine</i> , 2022, 12, 92.	2.5	6
249	Low heart rate variability from 10-s electrocardiograms is associated with development of non-alcoholic fatty liver disease. <i>Scientific Reports</i> , 2022, 12, 1062.	3.3	6
250	J-shaped relationship between serum zinc levels and the severity of hepatic necro-inflammation in patients with MAFLD. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2022, 32, 1259-1265.	2.6	6
251	Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2309-e2317.	3.6	6
252	Low skeletal muscle mass is associated with more severe histological features of non-alcoholic fatty liver disease in male. <i>Hepatology International</i> , 2022, 16, 1085-1093.	4.2	6

#	ARTICLE	IF	CITATIONS
253	Insulin in Acute Coronary Syndrome: a Narrative Review with Contemporary Perspectives. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 493-504.	2.6	5
254	Treatment algorithm in patients with type 2 diabetes and atherosclerotic cardiovascular disease or high/very high cardiovascular risk. <i>European Heart Journal</i> , 2020, 41, 331-331.	2.2	5
255	Factors independently associated with cardiorespiratory fitness in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2020, 40, 2998-3007.	3.9	5
256	Dysregulated Neurovascular Control Underlies Declining Microvascular Functionality in People With Non-alcoholic Fatty Liver Disease (NAFLD) at Risk of Liver Fibrosis. <i>Frontiers in Physiology</i> , 2020, 11, 551.	2.8	5
257	PNPLA3 polymorphism influences the association between high-normal TSH level and NASH in euthyroid adults with biopsy-proven NAFLD. <i>Diabetes and Metabolism</i> , 2020, 46, 496-503.	2.9	5
258	Associations of Hydroxysteroid 17-beta Dehydrogenase 13 Variants with Liver Histology in Chinese Patients with Metabolic-associated Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	5
259	Update on cardiovascular risk in nonalcoholic fatty liver disease. <i>Current Opinion in Cardiology</i> , 2021, 36, 478-486.	1.8	5
260	Fasting Ketonuria and the Risk of Incident Nonalcoholic Fatty Liver Disease With and Without Liver Fibrosis in Nondiabetic Adults. <i>American Journal of Gastroenterology</i> , 2021, 116, 2270-2278.	0.4	5
261	Decreased non-esterified fatty acid suppression and features of the insulin resistance syndrome occur in a sub-group of individuals with normal glucose tolerance. <i>Diabetologia</i> , 1995, 38, 1358-1366.	6.3	5
262	Potential Blood DNA Methylation Biomarker Genes for Diagnosis of Liver Fibrosis in Patients With Biopsy-Proven Non-alcoholic Fatty Liver Disease. <i>Frontiers in Medicine</i> , 2022, 9, 864570.	2.6	5
263	Prediabetes diagnosis is associated with the progression of coronary artery calcification: The Kangbuk Samsung Health Study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2118-2126.	4.4	5
264	Does tumour necrosis factor α influence insulin sensitivity in skeletal muscle?. <i>Clinical Science</i> , 2000, 99, 329-330.	4.3	4
265	Ethnicity and the Metabolic Syndrome. , 2006, , 43-84.		4
266	Change in fatty liver status and 5-year risk of incident metabolic syndrome: a retrospective cohort study. <i>Clinical Hypertension</i> , 2015, 21, 22.	2.0	4
267	Nonalcoholic fatty liver disease, cardiovascular outcomes, and mortality in patients undergoing a coronary angiogram. <i>Hepatology</i> , 2016, 64, 684-685.	7.3	4
268	The Prospective Studies of Atherosclerosis (Proof-ATHERO) Consortium: Design and Rationale. <i>Gerontology</i> , 2020, 66, 447-459.	2.8	4
269	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	1.5	4
270	Radiomics based on fluoro-deoxyglucose positron emission tomography predicts liver fibrosis in biopsy-proven MAFLD: a pilot study. <i>International Journal of Medical Sciences</i> , 2021, 18, 3624-3630.	2.5	4

#	ARTICLE	IF	CITATIONS
271	Transient elastography in patients at risk of liver fibrosis in primary care: a follow-up study over 54 months. <i>BJGP Open</i> , 2021, , BJGPO.2021.0145.	1.8	4
272	Serum 25-hydroxy vitamin D and the risk of low muscle mass in young and middle-aged Korean adults. <i>European Journal of Endocrinology</i> , 2022, 186, 477-487.	3.7	4
273	Myocardial blood flow reserve is impaired in patients with aortic valve calcification and unobstructed epicardial coronary arteries. <i>International Journal of Cardiology</i> , 2017, 248, 427-432.	1.7	3
274	Liver fat content, non-alcoholic fatty liver disease, and risk of ischaemic heart disease. <i>European Heart Journal</i> , 2018, 39, 3398-3398.	2.2	3
275	Telomerase: a key player in the pathogenesis of non-alcoholic fatty liver disease?. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 811-819.	3.0	3
276	Interaction of <i>SAMM50</i> -rs738491, <i>PARVB</i> -rs5764455 and <i>PNPLA3</i> -rs738409 Increases Susceptibility to Nonalcoholic Steatohepatitis. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 10, 219-229.	1.4	3
277	The effect of wasting and stunting during severe acute malnutrition in infancy on insulin sensitivity and insulin clearance in adult life. <i>Journal of Developmental Origins of Health and Disease</i> , 2022, , 1-7.	1.4	3
278	Why are there no strategies for NAFLD?. <i>Journal of Hepatology</i> , 2022, 76, 763-764.	3.7	3
279	Lower serum copper concentrations are associated with higher prevalence of nonalcoholic steatohepatitis: a matched case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , 2022, 34, 838-843.	1.6	3
280	Association between decreasing estimated glomerular filtration rate and risk of cardiac conduction defects in patients with type 2 diabetes. <i>Diabetes and Metabolism</i> , 2018, 44, 473-481.	2.9	2
281	Does high LDL-cholesterol cause cardiovascular disease?. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 91-91.	3.1	2
282	Diabetes is associated with increased risk of hepatocellular carcinoma in non-alcoholic steatohepatitis with cirrhosis—implications for surveillance and future pharmacotherapy. <i>Hepatobiliary Surgery and Nutrition</i> , 2020, 9, 230-234.	1.5	2
283	Identification and Functional Characterization of a Novel 27bp Deletion in the Macroglycopeptide-Coding Region of the <i>GP1bβ</i> Gene Resulting in Platelet-Type Von Willebrand Disease.. <i>Blood</i> , 2004, 104, 1023-1023.	1.4	2
284	Activated Protein C Resistance: Effect of Platelet Activation, Platelet-Derived Microparticles, and Atherogenic Lipoproteins. <i>Blood</i> , 1999, 93, 3792-3797.	1.4	2
285	Glycemic control predicts the risk of hepatic fibrosis in biopsy-proven NAFLD: a possible mediating role for leukemia inhibitory factor?. , 2022, 1, 30-34.		2
286	Liver fat in adult survivors of severe acute malnutrition. <i>Scientific Reports</i> , 2022, 12, 3690.	3.3	2
287	The role of insulin and proinsulin in the regulation of triglyceride metabolism. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 29-35.	1.2	1
288	Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2004, 6, 308-309.	4.4	1

#	ARTICLE	IF	CITATIONS
289	Oxidative Stress, Insulin Resistance and Cardiovascular Disease. , 2006, , 189-205.		1
290	Treatments for the Metabolic Syndrome. , 2006, , 381-406.		1
291	Adipocytokines and the Pathogenesis of the Metabolic Syndrome. , 2006, , 239-262.		1
292	Treating non-alcoholic fatty liver disease. Practice Nursing, 2007, 18, 120-126.	0.1	1
293	Glycaemic control and lipid concentrations in a cohort of people with diabetes over 7 years of follow-up: a regional audit of diabetes care in the UK. Diabetic Medicine, 2016, 33, 386-390.	2.3	1
294	Reply to: Fructose, uric acid and zonal differences in NASH. Journal of Hepatology, 2017, 67, 1118-1119.	3.7	1
295	<i>PNPLA3</i> rs738409 C>G Variant Influences the Association Between Visceral Fat and Significant Fibrosis in Biopsy-proven Nonalcoholic Fatty Liver Disease. Journal of Clinical and Translational Hepatology, 2022, 10, 439-448.	1.4	1
296	Atherothrombosis and the Metabolic Syndrome. , 0, , 163-187.		1
297	Sleep Duration, Sleep Quality, and the Development of Nonalcoholic Fatty Liver Disease: A Cohort Study. Clinical and Translational Gastroenterology, 2021, 12, e00417.	2.5	1
298	Fasting ketonuria is inversely associated with coronary artery calcification in non-diabetic individuals. Atherosclerosis, 2022, 348, 1-7.	0.8	1
299	Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease. Frontiers in Pediatrics, 0, 10, .	1.9	1
300	Growth Hormone, Exercise and Energy Expenditure in the Metabolic Syndrome. , 2006, , 353-380.		0
301	Inflammation, Cardiovascular Disease and the Metabolic Syndrome. , 2006, , 207-238.		0
302	Developmental Origins of Insulin Resistance and Type 2 Diabetes. , 2006, , 123-142.		0
303	Recent Progress in the Identification of Genes Predisposing to the Metabolic Syndrome. , 2006, , 143-162.		0
304	Developmental Origins of Vascular Dysfunction and Disease. , 2006, , 85-122.		0
305	Nutrition: It's Relevance in Development and Treatment of the Metabolic Syndrome. , 2006, , 333-352.		0
306	Insulin resistance and cortisol metabolism. Reply to Kerstens MN, Dullaart RPF [letter]. Diabetologia, 2007, 50, 2025-2026.	6.3	0

#	ARTICLE	IF	CITATIONS
307	A single enteral feed prior to the commencement of parenteral nutrition ameliorates the incidence of steatosis in parenterally fed neonatal piglets. <i>Metabolomics</i> , 2011, 7, 118-125.	3.0	0
308	Towards a personalised diagnosis of type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2013, 1, 6-7.	11.4	0
309	Insulin-induced hypoglycaemia and the detection of myocardial injury using an ultrasensitive troponin assay. <i>International Journal of Cardiology</i> , 2016, 215, 446-448.	1.7	0
310	PCSK9 inhibition for primary prevention of ischaemic heart disease in heterozygous familial hypercholesterolaemia. <i>The Cochrane Library</i> , 0, , .	2.8	0
311	Reply to: "Energy drinks and adolescents – A hepatic health hazard?" <i>Journal of Hepatology</i> , 2018, 68, 857-858.	3.7	0
312	Nutritional Targeting of Cancer Cell Metabolism in Obesity. <i>Journal of Nutrition</i> , 2018, 148, 1207-1208.	2.9	0
313	The evaluation of the repeatability of the ¹³ C-ketoisocaproate breath test for assessing hepatic mitochondrial function. <i>Isotopes in Environmental and Health Studies</i> , 2019, 55, 150-160.	1.0	0
314	Letter: non-alcoholic fatty liver disease is associated with a history of osteoporotic fractures but not with low bone mineral density" authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 961-962.	3.7	0
315	Fatty liver disease and changes in dense breasts in pre- and postmenopausal women: the Kangbuk Samsung Health Study. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 343-353.	2.5	0
316	Decreased microvascular functional vasodilatory reserve and features of the metabolic syndrome. <i>FASEB Journal</i> , 2008, 22, 1141.18.	0.5	0
317	An Experimental Series Investigating the Effects of Hyperinsulinemic Euglycemia on Myocardial Blood Flow Reserve in Healthy Individuals and on Myocardial Perfusion Defect Size following ST-Segment Elevation Myocardial Infarction. <i>Journal of the American Society of Echocardiography</i> , 2020, 33, 868-877.e6.	2.8	0
318	NAFLD and Cardiovascular and Cardiac Disease: Clinical Implications. , 2020, , 169-197.		0
319	Does tumour necrosis factor alpha influence insulin sensitivity in skeletal muscle?. <i>Clinical Science</i> , 2000, 99, 329-30.	4.3	0
320	Review: fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. <i>ACP Journal Club</i> , 2005, 142, 18.	0.1	0
321	Review: Fluoxetine, orlistat, and sibutramine modestly reduce weight in type 2 diabetes. <i>ACP Journal Club</i> , 2005, 142, 18.	0.1	0
322	How should endocrinologists diagnose and treat non-alcoholic fatty liver disease?. <i>Lancet Diabetes and Endocrinology</i> , 2022, 10, 478-480.	11.4	0